Table 3

Risk of extra-criteria manifestations in APS by univariable and multivariable logistic regression analysis

	Univariable regression analysis		Multivariable regression model—model 1*		Multivariable regression model—model 2†
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
Secondary APS	6.35 (2.90 to 13.92)	<0.001	6.19 (2.41 to 15.87)	<0.001	5.60 (2.20 to 14.29)	<0.001
Demographic features
Female	0.84 (0.44 to 1.62)	0.61
Age at diagnosis	1.00 (0.97 to 1.03)	0.98
BMI	0.93 (0.86 to 1.01)	0.10
Conventional risk factor
Diabetes mellitus	5.06 (0.58 to 44.28)	0.14
Arterial hypertension	5.56 (2.15 to 14.38)	<0.001	9.48 (3.06 to 29.34)	<0.001	9.08 (2.94 to 28.03)	<0.001
Smoking	0.96 (0.44 to 2.07)	0.91
Coronary artery disease	0.18 (0.02 to 1.61)	0.08
Immunological profile
ANA positivity	2.77 (1.48 to 5.18)	0.001
Low complement	3.27 (1.66 to 6.48)	0.001
Coombs’ test positivity	4.99 (2.25 to 11.06)	<0.001	3.53 (1.37 to 9.07)	0.01	3.36 (1.30 to 8.66)	0.01
LAC positivity	5.68 (1.83 to 17.60)	0.003
Anti-β2GPI IgG/M positivity	1.37 (0.73 to 2.57)	0.330
aCL-IgG/M positivity	3.49 (1.85 to 6.56)	<0.001
Single aPL positivity	0.36 (0.19 to 0.69)	0.002
Double aPL positivity	0.64 (0.29 to 1.41)	0.27
Triple aPL positivity	3.73 (1.94 to 7.16)	<0.001			3.00 (1.37 to 6.57)	0.01
Anti-β2GPI-DI IgG positivity	3.07 (1.55 to 6.08)	0.001	2.94 (1.29 to 6.70)	0.01
C-index			0.83 (0.77 to 0.90)		0.83 (0.77 to 0.90)

Single, double and triple refers to the positive numbers of the criteria aPLs, including aCL IgG/M, anti-β2GPI IgG/M antibodies and LAC.
*Model 1 was adjusted for secondary APS, arterial hypertension, Coombs’ test positivity and anti-β2GPI-DI IgG positivity.
†Model 2 was adjusted for secondary APS, arterial hypertension, Coombs’ test positivity and triple aPL positivity.
aCL, anticardiolipin; Anti-β2GPI-DI, anti-β2GPI-domain I; aPL, antiphospholipid antibodies; APS, antiphospholipid syndrome; BMI, body mass index; LAC, lupus anticoagulant.